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To evaluate the diagnosis and treatment of asymptomatic bacteriuria
(ASB) within a community hospital setting.

BACKGROUND
• Asymptomatic bacteriuria (ASB) is defined as bacteria in a urine
specimen without signs or symptoms of a urinary tract infection.1
• In 2019, the Infectious Diseases Society of America published clinical
practice guidelines for the management of ASB. These guidelines
provided more concrete definitions to aid in the diagnosis of ASB.1
• These guidelines state that the screening and treatment of ASB is only
appropriate in women who are pregnant.1
• Populations such as functionally impaired older adults residing in the
community, older residents residing in long term care facilities, and
diabetics should not be screened or treated for ASB.1
• Based on increasing antimicrobial resistance, along with an emphasis
on antimicrobial stewardship, the accuracy of diagnosing and treating
urinary laboratory results is of most importance.1-2

RESULTS

Table 1: Demographics
# of Patients
12
38

Male
Female

Table 2: Provider Specialty Ordering

Average Age (SD)
73.8 (± 16.6)
69.2 (± 9.4)

Antibiotics in ASB Inappropriate Group

Internal Medicine
Emergency Medicine
Cardiology
Pulmonary Disease
Cardiovascular Disease

Figure 1: Provider Specialty of UA and UCs Ordered
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Figure 2: Percentage of ASB and UTI Categories
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Figure 3: Percentage of UC Bacteria
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Table 5: Cost in ASB
Inappropriate Group
Total doses administered

59

Total cost of antibiotics

$78

Total cost of UA and UC

$1,150

DISCUSSION & CONCLUSIONS
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METHODS
• This Institutional Review Board (IRB) approved quality improvement
project was a retrospective chart review including patients with a
resulted urine analysis (UA) during hospitalization between July 2019
and July 2020.
• Exclusion criteria: Patients with complicating factors, such as, urinary
stent placement, spinal cord injury, history of kidney transplant,
sexually transmitted diseases, pyelonephritis diagnosis, candida
diagnosis.
• Data extracted from the electronic medical record (EMR) included
patient gender and age, urine analysis and culture results,
antimicrobial administration data, and ordering provider specialty of
both the UA and antimicrobials.
• Extensive manual data collection was needed to identify urinary
specific and non-specific symptoms at the time the UA was ordered
and to determine if an alternative source of infection within the
differential diagnosis resulted in an indication for antimicrobial use.
• Standard definitions were developed to group each patient into one of
four categories:
• ASB Appropriate: asymptomatic, no antimicrobial treatment
• ASB Inappropriate: asymptomatic, received antimicrobial treatment
• UTI Appropriate: symptomatic, received antimicrobial treatment
• UTI Inappropriate: symptomatic, no antimicrobial treatment
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• The diagnosis and treatment of ASB within the community hospital setting
appears to be less than optimal.
• Patients who presented with non-specific symptoms had a significant risk
of being misdiagnosed as UTI rather than ASB, and thus treated
inappropriately.
• Due to a low patient enrollment, further assessment should be considered
before extrapolating to a large population.
• Regardless, these results suggest that there is ongoing inappropriate
ordering of UAs, and subsequent UCs, which lead to increase in
unnecessary cost to the patient and institution.
• Over 5,600 patients qualified for our study. Applying this data to a
population this size, the organization could potentially save ~$137,500 a
year by optimizing care of ASB.
• Expanding on this patient population by collecting more data on the
current prevalence and treatment of ASB will allow for strong, accurate
conclusions to be drawn. These conclusions can then be applied
in practice.
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